Latest Conference Coverage

Subcutaneous Immunoglobulin Effective Alternative to Intravenous for Myasthenia Gravis

Subcutaneous immunoglobulin is an effective and well-tolerated alternative to intravenous immunoglobulin for myasthenia gravis.

Eculizumab's Myasthenia Gravis Benefits Sustained in Long-Term Extension Study

Eculizumab showed sustained activity and tolerability through 3 years for generalized myasthenia gravis.

Richard Rudick, MD: Using Data to Personalize MS Care

The vice president of Medical Research at Biogen spoke about the intersection between high-quality data utilization and individualized medicine in multiple sclerosis.

John Corboy, MD: Taking Patients Off Of Disease-Modifying Therapy

The professor of neurology at the University of Colorado posited that if certain criteria are met, it could be appropriate to take patients with multiple sclerosis off of DMT.

Earlier Treatment With Ocrelizumab Shows Favorable Results in Relapsing, Primary Progressive MS

Data from multiple open-label extension trials have suggested that the therapy is more beneficial with earlier initiation compared to interferon ß-1a.

Eva Winnebeck, PhD: Temporal Dynamics of Sleep

The postdoctoral scientist spoke about an actimetry-based method studying the clinical relevance of temporal dynamics of sleep to make the dynamics easily quantifiable in everyday context.

Johan Verbraecken, MD, PhD: Challenges in Conducting Clinical Trials in OSA

The medical coordinator of the Multidisciplinary Sleep-Wake Disorders Center at Antwerp University Hospital spoke about how to address some of the issues faced in OSA treatment development.

Tessa Blanken, MSc: Identification of Robust, Clinically Relevant Insomnia Subtypes

The identification of the subtypes allows future studies to target homogeneous subtype samples, resolve inconsistencies, personalize treatment and utilize preventive interventions.

Danny Eckert, PhD: Pharmacotherapies Reducing OSA Severity

Proof-of-concept studies using a targeted phenotypic approach to reduce obstructive sleep apnea severity are showing exciting results.

Danny Eckert, PhD: Unlocking New Targets For Pharmacological Therapy In OSA

The identification of 3 key non-anatomical contributors to OSA has unlocked new potential pharmacotherapies, a major advance for the field.

Jan Hedner, MD, PhD: Current Therapeutic Landscape of Obstructive Sleep Apnea

Recent research has identified novel potential pathophysiological mechanisms that could potentially serve to subclassify various phenotypes in obstructive sleep apnea.

Eva Winnebeck, PhD: Movement Rhythms During Sleep

The actimetry-based method allows for easily quantifiable sleep dynamics in real life context, enabling large-scale clinical studies to investigate the complex temporal dynamics of sleep.

Krista Lanctot, PhD: Managing Patients with Agitation

Lanctôt advised ruling out any possible underlying medical conditions that could be causing it, including pain, as well as starting with any non-pharmacologic interventions.

Geert Mayer, MD: Safety, Efficacy of Solriamfetol for Excessive Sleepiness In Narcolepsy, OSA

Long-term maintenance of efficacy was demonstrated with solriamfetol for treatment of excessive sleepiness with narcolepsy or obstructive sleep apnea.

Irina Pikuleva, PhD: Activating CYP46A1 with Efavirenz

The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University spoke about the beginnings of her work with efavirenz.

Geert Mayer, MD: Solriamfetol As Potential Therapy for Excessive Sleepiness in Narcolepsy, Obstructive Sleep Apnea

The neurologist and sleep specialist spoke about data from one of many studies investigating solriamfetol for treatment of narcolepsy and obstructive sleep apnea with remaining excessive daytime sleepiness.

Paul Newhouse, MD: Attacking Different Targets in Alzheimer

The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine shared his feelings on the early phase treatments.

Daphne Chylinski: Arousals During Sleep Are Strongly Linked to Alzheimer Disease Pathophysiology

Chylinski spoke about the relationship between the increased number of arousals during sleep and the pathogenesis of Alzheimer disease.

Howard Fillit, MD: The Importance of Biomarkers for Alzheimer Disease

Fillit spoke about remaining need for additional biomarkers in Alzheimer, and what has been developed in recent years.

Krista Lanctot, PhD: Addressing Alzheimer Disease Agitation

The psychiatry and pharmacology professor at the University of Toronto and senior scientist at Sunnybrook Research Institute spoke about the use of cannabinoids to treat agitation in Alzheimer.

Irina Pikuleva, PhD: Using Efavirenz in Alzheimer Disease

The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University further discussed the trial of efavirenz in AD.

Eugenia Trushina, PhD: Communication and Learning Through Collaboration

For the associate professor of neurology, learning, listening, and collaborating are the keys to improving the field of care.

Paul Newhouse, MD: Exploring VU319 in Alzheimer Disease

The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine explained more about the molecule and the subsequent trial of it.

Howard Fillit, MD: Emphasizing Care in Alzheimer Disease

With a heavy focus on the need for new treatments in Alzheimer, there remains a need to ensure patients are cared for first and foremost.

Biomarker Research Required to Further Advance Alzheimer Drug Discovery

Novel biomarkers are being explored to help expedite the development of new treatments for Alzheimer disease.

Ronald Crystal, MD: Introducing Genetics into Alzheimer Disease

Could the introduction of gene therapies into the Alzheimer space be the beginning of a new era of treatment?

Eugenia Trushina, PhD: Mitochondria as a Therapeutic Target for Alzheimer

The associate professor of neurology at Mayo Clinic spoke about targeting mitochondria to treat neurologic disorders.

Howard Fillit, MD: Alzheimer Disease Drug Development Improvement

The ADDF's founding executive director and chief scientific officer spoke about the gains in clinical trials in the last 5 years.

Allogeneic Mesenchymal Stem Cells Under Exploration for Alzheimer Disease, Aging Frailty

Allogeneic mesenchymal stem cells manufactured by Longeveron are advancing through phase I and II clinical trials.

Ronald Crystal, MD: APOE2 Gene Therapy for Alzheimer Disease

The chairman of the Department of Genetic Medicine at Weill Cornell Medicine shared his experience with the therapy and its potential in the space.